The Study
GLP-1 Analogues in the Neurobiology of Addiction: Translational Insights and Therapeutic Perspectives
This study is like a school report that summarizes what other scientists have found. It doesn't do new experiments, but it puts together lots of information from animal and human studies to explain how GLP-1 drugs might affect addiction. We can learn what might be happening, but we can't be sure it's true for most people.
Analysis score
Maximum 5 for a narrative review.
Where the score came from
Some medicines used for diabetes and weight loss might also help people stop using drugs or alcohol by changing how the brain feels reward.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 51 / 100
Quality score
Based on clinical experience or non-systematic literature reviews. The lowest level of evidence as they are most susceptible to bias and personal perspective.
Key takeaways
Summary
Based on the study abstract and findings.
- 1This could be important because addiction is hard to treat, and new medicines are needed—especially for people with both addiction and metabolic problems.
- 2In animals, these drugs made them take less alcohol, nicotine, and other drugs.
- 3They also had less desire to use drugs again after stopping.
- 4In people, early studies show possible help, especially if they have obesity.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
International Journal of Molecular Sciences
Year
2025
Authors
Juan David Marquez-Meneses, Santiago Arturo Olaya-Bonilla, Samuel Barrera-Carreño, Lucía Catalina Tibaduiza-Arévalo, Sara Forero-Cárdenas, Liliana Carrillo-Vaca, Luis Carlos Rojas-Rodríguez, C. Calderón-Ospina, J. Rodríguez-Quintana
Related Content
Claims (6)
Diabetes drugs called GLP-1 agonists might help people overcome addictions by reducing how pleasurable substances like alcohol, nicotine, and opioids feel in the brain.
A type of diabetes drug might help reduce cravings and relapse in addiction by affecting brain signals tied to pleasure and reward — at least in animals.
Medicines that target the GLP-1 brain system can reduce cravings for drugs without making enjoyable things feel less fun, at least in animal studies.
Diabetes drugs like Ozempic might help with addiction by calming brain reward signals when someone is high, easing withdrawal symptoms like stress, and reducing cravings when they see triggers.
Some parts of the brain that control pleasure and addiction have special spots (called GLP-1 receptors) that certain drugs can target, which might help reduce addictive behaviors by affecting brain chemicals like dopamine.
People with obesity or insulin resistance might cut down on alcohol and drugs more if they take GLP-1 drugs like Ozempic, according to early research hints.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.